Overall, the distribution of NAALADL2 and TBL1XR1 alterations were significantly different between disease sub-types to that which is expected (Chi-squared goodness-of-fit test: p = 1.19 × 10−6 and p = 2.39 × 10−6, Fig. 1a, b), with gains being most frequent in castrate-resistant prostate cancer (26.98% and 25.4% respectively), followed by neuroendocrine (20.45% and 20.45%), metastatic (5.69% and 7.58%) then primary prostate cancer (2.22% and 1.93%, Fig. 1a, b). The gene discussed is NAALADL2; the disease is prostate carcinoma.